ConserV Bioscience and Lawrence Livermore National Laboratory to Collaborate on Development of Broad-spectrum Coronavirus Vaccine
Share this article Share this article LONDON, Jan. 19, 2021 /PRNewswire/ -- ConserV Bioscience Limited ("ConserV"), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases and Lawrence Livermore National Laboratory ("LLNL") have agreed to collaborate on the development of a broad-spectrum coronavirus vaccine. This collaboration brings together ConserV's expertise in identifying antigens and Lawrence Livermore National Laboratory's nanolipoprotein particle technology ("NLP") delivery system. The vaccine has been desi...
Source: prnewswire.com